Prominent response to savolitinib monotherapy in high-grade fetal adenocarcinoma with amplification and concurrent brain metastasis: a case report.

BACKGROUND

Mesenchymal-epithelial transition () represents a potential therapeutic target in various cancers, with amplification of the gene identified in a subset of patients with pulmonary adenocarcinomas. However, gene amplification is rarely observed in high-grade fetal adenocarcinoma (H-FLAC).

CASE DESCRIPTION

Here we present a novel case of a patient diagnosed with stage IV H-FLAC harboring amplifications and treated with savolitinib. The 69-year-old male patient, who presented with a primary complaint of cough and white sputum, had a history of hypertension for over 10 years and a 45-year smoking history. The patient received savolitinib monotherapy treatment due to brain metastases. Despite the omission of radiotherapy for asymptomatic brain metastases, a notable response to savolitinib therapy was observed, with a partial response (PR) achieved after 4 weeks and a reduction in the brain tumor. At the time of the submission of this report, the patient received over 24 weeks of savolitinib treatment, and was maintained PR. The patient was still undergoing treatment. This highlights the potential clinical benefits of targeted therapy against amplification in H-FLAC.

CONCLUSIONS

H-FLAC harboring amplification and brain metastasis is rare. Treatment with savolitinib monotherapy resulted in a PR, providing preliminary insights to the efficacy of savolitinib for H-FLAC with amplification.